Complement C3 and cleavage products in cardiometabolic risk
- 15 March 2011
- journal article
- review article
- Published by Elsevier in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 412 (13-14), 1171-1179
- https://doi.org/10.1016/j.cca.2011.03.005
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort studyEuropean Journal of Preventive Cardiology, 2007
- Type 2 diabetes and cardiovascular disease: getting to the fat of the matterThis paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.Canadian Journal of Physiology and Pharmacology, 2007
- Cross-sectional study of complement C3 as a coronary risk factor among men and womenClinical Science, 2005
- Critical review of acylation-stimulating protein physiology in humans and rodentsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2002
- Phylogenetic aspects of the complement systemDevelopmental & Comparative Immunology, 2001
- Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged menEuropean Heart Journal, 2000
- Regulation of complement activation by C-reactive proteinImmunopharmacology, 1999
- Association of serum C3 levels with the risk of myocardial infarctionAmerican Journal Of Medicine, 1995
- The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis.Journal of Clinical Investigation, 1993
- Human C′3: Evidence for the Liver as the Primary Site of SynthesisScience, 1969